The Myasthenia Gravis Foundation of America (MGFA) awarded four grants, each valued at $110,000, to research projects aimed at better understanding the biology of myasthenia gravis (MG) and improving its diagnosis and treatment. “MGFA is helping to fuel a sea change in myasthenia gravis diagnosis and care,” Samantha…
News
Vyvgart (efgartigimod alfa-fcab) and Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) are now approved in the U.S. to treat all adults with generalized myasthenia gravis (gMG), regardless of antibody status. The U.S. Food and Drug Administration (FDA) initially approved Vyvgart in 2021 and Vyvgart Hytrulo in…
Dianthus Therapeutics is on track to launch by midyear a late-stage clinical trial to confirm the safety and effectiveness of claseprubart (DNTH103), its experimental injection therapy, in people with generalized myasthenia gravis (gMG). The Phase 3 study, called EMERGE, will be registrational, meaning it will be designed to…
Switching from intravenous immunoglobulin (IVIG) to Vyvgart (efgartigimod alfa) was associated with fewer hospitalizations and better quality-of-life scores after the switch in people with generalized myasthenia gravis (gMG), according to a study in Japan. Also, a greater proportion of patients transitioning to Vyvgart achieved minimal manifestations, a…
The National Institute for Health and Care Excellence (NICE) has recommended that Rystiggo (rozanolixizumab-noli) be covered by England’s National Health Service (NHS) and provided at low or no cost to certain adults with hard-to-treat generalized myasthenia gravis (gMG). The recommendation makes Rystiggo the first gMG therapy to be…
A thymectomy, the surgical removal of the thymus gland, was projected to improve health outcomes and lower lifetime care costs when added to prednisolone-based care for eligible adults with myasthenia gravis (MG) in the U.K. Simulations in the study, which focused on eligible adults with generalized MG and…
The Tensilon test, though no longer used in the U.S., is generally safe and can accurately identify people with myasthenia gravis (MG) versus those without the autoimmune disease, according to a large study in Austria that assessed the effectiveness of the diagnostic tool. Also known as the edrophonium…
Nearly one in three people with generalized myasthenia gravis (gMG) experienced prolonged periods of few or no symptoms while on treatment with Imaavy (nipocalimab-aahu), according to more than two years of data from a global clinical trial. These and other data from the…
An investigational autoinjector device for administering Zilbrysq (zilucoplan), an approved therapy for generalized myasthenia gravis (gMG), is a safe and effective option for individuals now using the currently available prefilled syringe, according to new data from two clinical trials. Users were “highly satisfied” with the Zilbrysq autoinjector and…
Cemdisiran, an experimental therapy given by injection under the skin every three months, was shown to significantly and sustainably ease symptoms of generalized myasthenia gravis (gMG) in a global, late-stage clinical trial called NIMBLE. In addition to suggesting that cemdisiran is an effective gMG treatment, the trial results…
Recent Posts
- The parts of MG people don’t see when they look at me
- Building confidence, not in spite of myasthenia gravis, but by living with it
- Goal for this gMG patient advocate is expanded access to new treatments
- MDA events seek to build community and help families navigate care
- Lessons from my late father on coping with loss in life with MG